These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 20927319)

  • 1. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
    Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
    Ashida R; Nakata B; Shigekawa M; Mizuno N; Sawaki A; Hirakawa K; Arakawa T; Yamao K
    J Exp Clin Cancer Res; 2009 Jun; 28(1):83. PubMed ID: 19531250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
    Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R
    Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
    Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
    Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
    Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
    Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.
    Eto K; Kawakami H; Kuwatani M; Kudo T; Abe Y; Kawahata S; Takasawa A; Fukuoka M; Matsuno Y; Asaka M; Sakamoto N
    Br J Cancer; 2013 Apr; 108(7):1488-94. PubMed ID: 23492684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
    Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
    Wei CH; Gorgan TR; Elashoff DA; Hines OJ; Farrell JJ; Donahue TR
    Pancreas; 2013 Nov; 42(8):1303-10. PubMed ID: 24152955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y; Tanno S; Koizumi K; Nishikawa T; Nakamura K; Minoguchi M; Izawa T; Mizukami Y; Okumura T; Kohgo Y
    Br J Cancer; 2007 Feb; 96(3):457-63. PubMed ID: 17224927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
    Mori R; Ishikawa T; Ichikawa Y; Taniguchi K; Matsuyama R; Ueda M; Fujii Y; Endo I; Togo S; Danenberg PV; Shimada H
    Oncol Rep; 2007 May; 17(5):1201-5. PubMed ID: 17390066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
    Nakamura J; Kohya N; Kai K; Ohtaka K; Hashiguchi K; Hiraki M; Kitajima Y; Tokunaga O; Noshiro H; Miyazaki K
    Int J Oncol; 2010 Oct; 37(4):845-52. PubMed ID: 20811706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
    Murata A; Amano R; Yamada N; Kimura K; Yashiro M; Nakata B; Hirakawa K
    World J Surg Oncol; 2013 May; 11():117. PubMed ID: 23710668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
    Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
    Kim R; Tan A; Lai KK; Jiang J; Wang Y; Rybicki LA; Liu X
    Cancer; 2011 Jul; 117(14):3126-34. PubMed ID: 21264835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
    Sasaki H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Br J Cancer; 2014 Sep; 111(7):1275-84. PubMed ID: 25032731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.
    Toffalorio F; Giovannetti E; De Pas T; Radice D; Pelosi G; Manzotti M; Minocci D; Spaggiari L; Spitaleri G; Noberasco C; Catania C; Boselli S; Danesi R; de Braud F
    Pharmacogenomics J; 2010 Jun; 10(3):180-90. PubMed ID: 19901957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.